



**Supplemental Figure 1. Glycolytic pool sizes in failing MPC<sup>-/-</sup> hearts.** **A**, Schematic pathway of glycolysis and accessory glucose pathways. **B** through **L**, Normalized pool size of glucose (**B**), glucose-6-phosphate (G6P) (**C**), fructose bisphosphate (FBP) (**D**), dihydroxyacetone phosphate (DHAP) (**E**), 2/3-phosphoglycerate (PG) (**F**), phosphoenolpyruvate (PEP) (**G**), pyruvate (**H**), lactate (**I**), alanine (**J**), and the <sup>13</sup>C % enrichment of glycerol 3-phosphate (Glycerol 3P) (**K**) and glycerol 3P pool (**L**) of failing CS-Mpc2<sup>-/-</sup> hearts and fl/fl littermates injected with U-<sup>13</sup>C-glucose, n=11-12. Data are presented as the mean±SD. Data were evaluated by unpaired, two-tailed Student's t-test with Welch correction.




**Supplemental Figure 2. TCA cycle enrichment and pool sizes in failing CS-Mpc2<sup>-/-</sup> hearts.** A through L, the <sup>13</sup>C % enrichment and pool sizes of citrate (A-B), aconitate (C-D),  $\alpha$ -ketoglutarate (KG) (E-F), succinate (G-H), fumarate (I-J), and malate (K-L) in fl/fl and failing CS-Mpc2<sup>-/-</sup> hearts of mice injected i.p. with U-<sup>13</sup>C-glucose, n=11-12. Data are presented as the mean $\pm$ SD. Data were evaluated by unpaired, two-tailed Student's t-test with Welch correction.




**Supplemental Figure 3. MPC deletion reduces pyruvate oxidation.** **A** and **B**, Oxygen consumption rates (OCR) measured from isolated cardiac mitochondria (**A**) and permeabilized cardiac muscle fibers (**B**) from hearts of fl/fl and CS-Mpc2<sup>-/-</sup> littermates stimulated with pyruvate/malate (P/M), P/M plus adenosine diphosphate (ADP), and P/M, ADP, and the MPC inhibitor UK-5099 (5  $\mu$ M), n=4-5. Data are presented as the mean $\pm$ SD. Data were evaluated by unpaired, two-tailed Student's t-test with Welch correction.


# Supplemental Fig 4: No major changes in the pentose phosphate pathway in failing MPC-/- hearts




**Supplemental Figure 4. No major changes in the pentose phosphate pathway in failing MPC<sup>-/-</sup> hearts. A,** Schematic of <sup>13</sup>C enrichment of the pentose phosphate pathway from U-<sup>13</sup>C-glucose. Metabolites in grey were not measured. **B** through **F**, <sup>13</sup>C % enrichment and normalized pool size of 6-phosphogluconate (PG) (**B**), ribose-5-phosphate (R5P) (**C**), sedoheptulose 7-phosphate (Sedo7P) (**D**), serine (**E**), and glycine (**F**), in hearts from fl/fl and failing CS-Mpc2<sup>-/-</sup> mice injected with U-<sup>13</sup>C-glucose, n=11-12. Data are presented as the mean±SD. Data were evaluated by unpaired, two-tailed Student's t-test with Welch correction.



**Supplemental Figure 5. Glycolytic pool sizes in young, non-failing MPC<sup>-/-</sup> hearts. A**, Schematic of glycolysis and accessory glucose pathways. **B through Q**, Normalized pool sizes of glucose (**B**), glucose-6-phosphate (G6P) (**C**), fructose bisphosphate (FBP) (**D**), dihydroxyacetone phosphate (DHAP) (**E**), 2/3 phosphoglycerate (PG) (**F**), phosphoenolpyruvate (PEP) (**G**), pyruvate (**H**), lactate (**I**), alanine (J), ribose-5-phosphate (R5P) (**K**), and the <sup>13</sup>C enrichment and pool size of serine (**L-M**), glycine (**N-O**), and glycerol 3-phosphate (glycerol 3P) (**P-Q**) in young non-failing CS-Mpc2<sup>-/-</sup> and fl/fl littermates injected with U-<sup>13</sup>C-glucose, n=8-10. Data are presented as the mean±SD. Data were evaluated by unpaired, two-tailed Student's t-test with Welch correction.



**Supplemental Figure 6. TCA cycle enrichment and pool sizes in young, non-failing CS-Mpc2<sup>-/-</sup> hearts.** A through L, <sup>13</sup>C % enrichment and normalized pool sizes of citrate (A-B), aconitate (C-D),  $\alpha$ -ketoglutarate ( $\alpha$ KG) (E-F), succinate (G-H), fumarate (I-J), and malate (K-L), in hearts of young, nonfailing CS-Mpc2<sup>-/-</sup> and fl/fl littermates injected with U-<sup>13</sup>C-glucose, n=8-10. Data are presented as the mean $\pm$ SD. Data were evaluated by unpaired, two-tailed Student's t-test with Welch correction.



**Supplemental Figure 7. Ketogenic diet decreases TCA cycle enrichment from glucose.** A through L,  $^{13}\text{C}$  % enrichment of pyruvate (A), lactate (B), alanine (C), citrate (D), aconitate (E),  $\alpha$ -ketoglutarate ( $\alpha$ KG) (F), glutamate (G), glutamine (H), succinate (I), fumarate (J), malate (K), and aspartate (L) in hearts from *fl/fl* and *CS-Mpc2<sup>-/-</sup>* fed either low-fat (LF) or ketogenic diet (KD) and injected with U- $^{13}\text{C}$ -glucose,  $n=6-7$ . Data are presented as the mean  $\pm$  SD. Data were evaluated by two-way analysis of variance (ANOVA) with Tukey post-hoc multiple-comparisons test.